BANCA MEDIOLANUM SPA (BMED.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:BMED - IT0004776628 - Common Stock
19.8 EUR
-0.04 (-0.2%)
BMED gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 59 industry peers in the Financial Services industry. While BMED is still in line with the averages on profitability rating, there are concerns on its financial health. BMED is valied quite expensively at the moment, while it does show a decent growth rate. Finally BMED also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
- BMED had positive earnings in the past year.
- BMED had a positive operating cash flow in the past year.
- In the past 5 years BMED has always been profitable.
- The reported operating cash flow has been mixed in the past 5 years: BMED reported negative operating cash flow in multiple years.
1.2 Ratios
- BMED has a Return On Assets (1.88%) which is in line with its industry peers.
- BMED's Return On Equity of 38.66% is amongst the best of the industry. BMED outperforms 89.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.88% | ||
| ROE | 38.66% | ||
| ROIC | N/A |
ROA(3y)1.24%
ROA(5y)1.08%
ROE(3y)27.98%
ROE(5y)24.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BMED has a Profit Margin of 20.36%. This is in the better half of the industry: BMED outperforms 77.97% of its industry peers.
- BMED's Profit Margin has improved in the last couple of years.
- BMED does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 20.36% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y16.85%
PM growth 5Y14.52%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- BMED does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for BMED has been reduced compared to 1 year ago.
- BMED has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for BMED has been reduced compared to a year ago.
2.2 Solvency
- The Debt to FCF ratio of BMED is 5.80, which is a neutral value as it means it would take BMED, 5.80 years of fcf income to pay off all of its debts.
- With a decent Debt to FCF ratio value of 5.80, BMED is doing good in the industry, outperforming 62.71% of the companies in the same industry.
- A Debt/Equity ratio of 0.99 indicates that BMED is somewhat dependend on debt financing.
- The Debt to Equity ratio of BMED (0.99) is worse than 66.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.99 | ||
| Debt/FCF | 5.8 | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACC7.6%
2.3 Liquidity
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | N/A | ||
| Quick Ratio | N/A |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 36.00% over the past year.
- BMED shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.21% yearly.
- Looking at the last year, BMED shows a decrease in Revenue. The Revenue has decreased by -4.20% in the last year.
- The Revenue has been growing slightly by 0.11% on average over the past years.
EPS 1Y (TTM)36%
EPS 3Y15.94%
EPS 5Y14.21%
EPS Q2Q%10%
Revenue 1Y (TTM)-4.2%
Revenue growth 3Y-0.53%
Revenue growth 5Y0.11%
Sales Q2Q%36.86%
3.2 Future
- The Earnings Per Share is expected to decrease by -0.57% on average over the next years.
- The Revenue is expected to grow by 0.90% on average over the next years.
EPS Next Y-4.88%
EPS Next 2Y-3.08%
EPS Next 3Y-0.57%
EPS Next 5YN/A
Revenue Next Year-6.87%
Revenue Next 2Y-1.14%
Revenue Next 3Y0.9%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- BMED is valuated correctly with a Price/Earnings ratio of 13.20.
- Based on the Price/Earnings ratio, BMED is valued a bit cheaper than 64.41% of the companies in the same industry.
- BMED's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.60.
- BMED is valuated correctly with a Price/Forward Earnings ratio of 14.09.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of BMED is on the same level as its industry peers.
- BMED is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 25.83, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.2 | ||
| Fwd PE | 14.09 |
4.2 Price Multiples
- The rest of the industry has a similar Price/Free Cash Flow ratio as BMED.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.59 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)0.93
EPS Next 2Y-3.08%
EPS Next 3Y-0.57%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 5.10%, BMED is a good candidate for dividend investing.
- BMED's Dividend Yield is rather good when compared to the industry average which is at 1.97. BMED pays more dividend than 88.14% of the companies in the same industry.
- BMED's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.1% |
5.2 History
- The dividend of BMED is nicely growing with an annual growth rate of 14.04%!
Dividend Growth(5Y)14.04%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- 45.69% of the earnings are spent on dividend by BMED. This is a bit on the high side, but may be sustainable.
DP45.69%
EPS Next 2Y-3.08%
EPS Next 3Y-0.57%
BANCA MEDIOLANUM SPA / BMED.MI FAQ
What is the ChartMill fundamental rating of BANCA MEDIOLANUM SPA (BMED.MI) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BMED.MI.
Can you provide the valuation status for BANCA MEDIOLANUM SPA?
ChartMill assigns a valuation rating of 3 / 10 to BANCA MEDIOLANUM SPA (BMED.MI). This can be considered as Overvalued.
Can you provide the profitability details for BANCA MEDIOLANUM SPA?
BANCA MEDIOLANUM SPA (BMED.MI) has a profitability rating of 4 / 10.
How financially healthy is BANCA MEDIOLANUM SPA?
The financial health rating of BANCA MEDIOLANUM SPA (BMED.MI) is 2 / 10.
What is the expected EPS growth for BANCA MEDIOLANUM SPA (BMED.MI) stock?
The Earnings per Share (EPS) of BANCA MEDIOLANUM SPA (BMED.MI) is expected to decline by -4.88% in the next year.